Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) CEO Jean-Pierre Sommadossi sold 56,910 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $3.85, for a total value of $219,103.50. Following the sale, the chief executive officer now owns 116,557 shares of the company’s […]
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Rating Lowered by JPMorgan Chase & Co. wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 1,830,000 shares, a growth of 9.6% from the June 30th total of 1,670,000 shares. Based on an average trading volume of 709,000 shares, […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 1,870,000 shares, a growth of 9.4% from the May 15th total of 1,710,000 shares. Approximately 2.6% of the company’s stock are short sold. Based on an average […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,790,000 shares, a drop of 5.8% from the March 15th total of 1,900,000 shares. Approximately 2.5% of the company’s stock are sold short. Based on an average […]